Home › Funds › BAKER BROS. ADVISORS LP › RYTM
BAKER BROS. ADVISORS LP position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 5,604,483 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$622.3M, representing 3.25% of its reported portfolio and ranking #9 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's RYTM position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in RYTM in Q3 2023 at 6,702,349 shares (US$153.7M). The position peaked in Q2 2026 at 5,604,483 shares, worth US$622.3M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 8 time(s). The most recent filing (Q2 2026) shows 5,604,483 shares valued at US$622.3M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 6.70M | $153.65M | New |
| Q4 2023 | 6.40M | $294.13M | Reduce |
| Q1 2024 | 6.40M | $277.24M | Hold |
| Q2 2024 | 6.40M | $262.72M | Hold |
| Q3 2024 | 6.40M | $335.21M | Hold |
| Q4 2024 | 6.08M | $340.60M | Reduce |
| Q1 2025 | 5.60M | $296.87M | Reduce |
| Q2 2025 | 5.60M | $354.15M | Hold |
| Q3 2025 | 5.60M | $566.00M | Hold |
| Q4 2025 | 5.60M | $599.90M | Hold |
| Q1 2026 | 5.60M | $487.42M | Hold |
| Q2 2026 | 5.60M | $622.27M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), PERCEPTIVE ADVISORS LLC (US$287.2M), WESTFIELD CAPITAL MANAGEMENT CO LP (US$245.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.21M sh · $245.22M · Q2 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Siren, L.L.C. 1.14M sh · $126.16M · Q2 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
- BRAIDWELL LP 381.13K sh · $42.32M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held RYTM?
BAKER BROS. ADVISORS LP has disclosed RYTM holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in RYTM?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 5.60M shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $622.27M, representing 3.25% of its reported portfolio and ranking #9.
Has BAKER BROS. ADVISORS LP been buying or selling RYTM?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in RYTM. The position peaked in Q2 2026 at 5.60M shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, WESTFIELD CAPITAL MANAGEMENT CO LP, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.